A venture capital-backed antibody company called Argen-x BV has raised €9.5 million in a Series A financing round from a syndicate of investors, co-led by Forbion Capital Partners and Life Sciences Partners, both of the Netherlands. ---Subscribe to MedNous to access this article--- Finance, Grants, Deals
